Comparative Pharmacology
Head-to-head clinical analysis: NEBUPENT versus PYRIMETHAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEBUPENT versus PYRIMETHAMINE.
NEBUPENT vs PYRIMETHAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nebupent (pentamidine isethionate) is an antimicrobial agent that inhibits the synthesis of DNA, RNA, phospholipids, and proteins in protozoa. Its mechanism may involve interference with polyamine synthesis and inhibition of dihydrofolate reductase.
Pyrimethamine inhibits dihydrofolate reductase (DHFR) in the parasite, blocking the conversion of dihydrofolate to tetrahydrofolate, thereby inhibiting nucleic acid synthesis.
300 mg via inhalation once every 4 weeks for prophylaxis of Pneumocystis jirovecii pneumonia.
For toxoplasmosis: 200 mg orally once, then 50-75 mg orally once daily for 4-6 weeks, plus sulfadiazine and folinic acid. For malaria prophylaxis: 25 mg orally once weekly.
None Documented
None Documented
Clinical Note
moderatePyrimethamine + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pyrimethamine."
Clinical Note
moderatePyrimethamine + Artemether
"The risk or severity of QTc prolongation can be increased when Pyrimethamine is combined with Artemether."
Clinical Note
moderatePyrimethamine + Lumefantrine
"The risk or severity of QTc prolongation can be increased when Pyrimethamine is combined with Lumefantrine."
Clinical Note
moderateTerminal elimination half-life: 6-9 hours (prolonged in renal impairment; clinical context: supports once-daily dosing for treatment, but prophylaxis may require reduced frequency in renal dysfunction)
Terminal elimination half-life is approximately 96 hours (range 80-123 hours) in adults with normal renal function; prolonged in renal impairment (up to 200 hours). This long half-life supports weekly dosing regimens.
Renal: approximately 90% as unchanged drug; biliary/fecal: minimal (<5%)
Primarily renal (approximately 30% unchanged and 20-30% as metabolites); additional biliary/fecal elimination (20-30% as metabolites). Total urinary excretion of parent drug and metabolites accounts for 60-80% of dose.
Category C
Category D/X
Antiprotozoal, Inhaled
Antimalarial / Antiprotozoal
Cyclophosphamide + Pyrimethamine
"The metabolism of Pyrimethamine can be decreased when combined with Cyclophosphamide."